Group B Streptococcus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine
June 19, 2017 Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. An estimated 10 to 30... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 19, 2017 Category: Pharmaceuticals Source Type: clinical trials
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
Condition: Group B Streptococcal Infections Interventions: Biological: Multivalent group B streptococcus vaccine; Biological: Placebo Sponsor: Pfizer Not yet recruiting - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2017 Category: Research Source Type: clinical trials